Skip to content

Heart Failure
Uncovered

Precision analysis powered by AI

Ultromics EchoGo streamlines the clinical workflow enabling clinicians confidently detect heart failure with and reduce the time taken to provide patients with therapies they urgently need.

New published research

JACC Advances: Automated Detection of HFpEF using AI

Fighting
against failure

Founded in the clinical excellence of Oxford University Ultromics EchoGo platform designated breakthrough device FDA approval harnesses artificial intelligence to help answer the healthcare crisis. We are the leader in artificial intelligence for echocardiography enabling earlier detection and risk stratification of heart failure for better outcomes, lower costs, and improved patient care. 

 



All providers, regardless of their care setting, can now make precise, accurate, and timely diagnoses of heart failure with Ultromics’ AI technology.

The beat of change

Proven feasibility sensitivity, and specificity.
Faster access to patient therapies
Access anywhere - cloud based AI automation streamlines workflow operations
Reduce indeterminate diagnoses

EchoGo

A new class of heart failure detection

Ultromics brings the power of artificial intelligence into your echocardiography workflow using a state-of-the-art platform that supports early heart failure diagnosis. EchoGo modules are designed with industry leaders in cardiac care to unlocka new pathway for heart failure care, bringing patients closer to a definitive diagnosis, accelerating earlier diagnosis and treatment, and helping to improve the lives of many.

EchoGo Heart Failure

EchoGo® Heart Failure is designed to identify the presence or absence of HFpEF to manage patients more effectively. Disease suspicion is highlighted through reports sent to physician workstations within 30 minutes, to support smart, decisive interpretation and reduces indeterminate results from 64% to 7%.

Using our FDA-cleared system, our platform has helped clinicians solve indeterminate cases and has helped providers reduce costs.

See more

EchoGo Amyloidosis

EchoGo® Amyloidosis is a state-of-the-art, AI-driven solution that offers insights to assist in cardiac examinations. Our technology employs deep learning to detect Cardiac Amyloidosis from any echocardiogram, using a single apical 4-chamber clip. We tackle the challenge of Cardiac Amyloidosis detection which is misdiagnosed in 57% of patients. Echo offers precise heart analysis within 30 minutes with unparalleled sensitivity and accuracy for cardiac amyloidosis, improving the detection of cardiac amyloidosis.

See more

“This novel solution applies AI to cardiovascular imaging to greatly simplify identification of patients with HFpEF, a diagnosis that can be challenging to make, and allow more expeditious treatment. - will be different quote”

Patricia A. Pellikka, MD. , Vice Chair, Department of Cardiovascular Medicine at Mayo Clinic

AI capabilities

Our unique service

Any vendor

Connects with any vendor in any care setting.

Dashboard

Customer report dashboard and smart analytics.

QC + secured

CyberEssentials, ISO 27001, and ISO 13485. HIPAA Compliance.

No training

No need to learn software. Always being optimized. 

Seamless

Simple and easy integration that fits with your workflow.

Cloud native

Operate on a cloud native architecture for optimal resource saving.

See our proof and validation

See more

Verified in clinical settings

Our current customers have indicated major improvements in their pain and process while using our EchoGo platform. Our technology is backed by collaborations with industry leading clincians, engineers, and research institutions.

Together with experts

Each of our partners are innovation leaders are working with us to make lives better.

We partner with exceptional leaders across all stages to build transformative technologies.

All partners

“The FNIH will harness valuable perspectives and expertise of a select number of collaborations, including Ultromics, to alleviate this unmet need and pave the way for better classification and more precise treatment strategies.”

Dr Julie Gerberding , Chief Executive Officer at the FNIH

Some of who we work with

Our impact across heart failure

Our platform has been used by hospitals worldwide, including Mayo Clinic, Northwestern and OHSU.
Born at the University of Oxford from leading minds in science, engineering, and AI.
Over $50 million raised with the likes of Blues Ventures, Optum, and Google Ventures.
Partners with The Foundation for the National Institutes of Health (FNIH) in redefining HFpEF classification.
Partners with leading amyloidosis pharmaceutical companies Johnson&Johnson Innovative medicine and Pfizer

We are redefining heart failure as we know it

Innovation is at the heart of everything we do

 

At the heart of our mission is a commitment to making heart failure detection easier for providers and prognosis better for patients. Healthcare professionals should receive critical information they need minimizing the added risks and costs of untreated patients or further procedures. Staying true to the standards set by our Oxford University origins, we are partnering with the most trusted and validated medical organizations in the world to improve quality of life and reduce the burden on the healthcare system at large.

More about Ultromics



100,000+

cases processed so far

10,000+

pixels analyzed by our AI algorithm

10 years

of outcome data

 

Knowledge Hub See more

80% of CVD Deaths are Preventable

No. 1 global killer

Find out how EchoGo aids in the interpretation and diagnosis of echocardiograms to reduce the time taken to provide effective therapies to patients 

Challenges Diagnosing HFpEF

Up to 64% of HFpEF patients undiagnosed

Effective HFpEF diagnosis suffers from a complicated diagnostic pathway due to similarities with HFrEF and no single standardised scoring symstem which suffer from a high degree of variability in senstivity and specificity for the diagnosis of HFpEF. In addition patients are often non symptomatic meaning invasive hemodynamic tests are required. 

See more

Challenges Diagnosing Cardiac Amyloidosis

Up to 57% of Cardiac Amyloidosis patients misdiagnosed

Electrocardiography is key in raising clinical suscipion of cardiac amyloidosis needed to commence the use of diagnostic techniques that have 100% accuracy however dificulties surrounding access to specialist doctors and high iner and intra reader variability mean CA is often misdiagnosed resulting in delays in treatment and worse patient outcomes.

See more

What are you waiting for?

Take the first step and contact us today.

Connect with us

Curious about upcoming research and innovation?

Sign-up to hear about the latest news. 

Get on our news list

References:

  1. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175:996–1004.
  2. Savarese G and Lund LH. Global public health burden of heart failure. Cardiac Failure Review. 2017;3:1:7-11.
  3. Borlaug, BA, Sharma K, Shah SJ, et al. Heart failure with preserved ejection fraction, :JACC Scientific Statement. Journal of the American College of Cardiology. 2023;81:1810–1834.
  4. Akerman AP, Porumb M, Beqiri A, et al. Comparison of clinical algorithms and artificial intelligence applied to an echocardiogram to categorize risk of heart failure with preserved ejection fraction. Journal of the American College of Cardiology. ACC. 2023;81 (8_Supplement) 360.
    *based on an example use case.

Curious about upcoming research and innovation?

Sign up to hear about the latest news. 

Sign up to newsletter